Maintenance for acute myeloid leukemia revisited

Current Treatment Options in Oncology

Volumn 8, Issue 4, 2007, Pages 296-304

  Büchner, Thomas ^a   Krug, Utz ^a   Berdel, Wolfgang E ^a   Heinecke, Achim ^b   Sauerland, Maria Cristina ^b   Wörmann, Bernhard ^b   Hiddemann, Wolfgang ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE DERIVATIVE; DAUNORUBICIN; LOMUSTINE; MERCAPTOPURINE; MITOXANTRONE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; LEUKEMIA REMISSION; LEUKEMOID REACTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROMYELOCYTIC LEUKEMIA; REPEATED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 38349018710     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0041-1     Document Type: Review

References (22)

1. Tallman MS, Andersen JW, Schiffer C, et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337: 1021-1028
2. Dombret H. Fenaux P, Soignet SL, Tallman M.: Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel target. Sem Hematol 2002, 39: 8-13
3. Bloomfield CD, Lawrence D, Byrd J, et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research 1998, 58: 4173-4179
4. Büchner T, Berdel WE, Schoch C, et al.: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006, 24: 2480-2489
5. Taeuber CM.: Sixty-five plus in America, Current Population Reports, Special Studies, Rev. ed. Washington, DC: U.S. Government Printing Office; 1993:23-178, RV
6. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review 1975-2000
7. Burnett AK, Goldstone AH, Stevens RMF, et al.: Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. Lancet 1998, 351: 700-708
8. Burnett AK, Wheatley K, Goldstone AH, et al.: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002, 118: 385-400
9. Suciu S, Mandelli F, de Witte T, et al.: Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myleoid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMA AML-10 trial. Blood 2003, 102: 1232-1240
10. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al.: Results of a HOVON/ SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 2007, 109: 3658-3666
11. Rai KR, Holland JF, Glidewell OJ, et al.: Treatment of acute myelocytic Leukemia: A study by Cancer and Leukemia Group B. Blood 1981, 58: 1203-1212
12. Büchner T, Hiddemann W, Berdel WE, et al.: 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21: 4496-4504
13. Büchner T, Urbanitz D, Hiddemann W, et al.: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3: 1583-1589
14. Preisler H, Davis RB, Kirshner J, et al.: Comparison of three remission inducition regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study. Blood 1987, 6: 1441-1449
15. Cassileth PA, Lynch E, Hines JD, et al.: Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992, 79: 1924-1930
16. Ohno R, Kobayashi T, Tanimoto M, et al.: Randomized study of individualized induction therapy with or without Vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 1993, 71: 3888-3895
17. Löwenberg B, Suciu S, Archimbaud E, et al.: Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group Randomized phase III study AML-9. J Clin Oncol 1998, 16: 872-881
18. Stone R, Berg DT, George SL, et al.: Postremission therapy in older patients with de-novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001, 98: 548-553
19. Goldstone AH, Burnett AK, Wheatley K, et al.: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001, 8: 1302-1311
20. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339: 1649-1656
21. Büchner T, Döhner H, Ehninger G, et al.: Up-front randomization and common standard arm: A proposal for comparing AML treatment strategies between different studies. Leuk Res 2002, 26: 1073-1075
22. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331: 896-942. Establishment of postremission therapy for AML by 4 courses of high-dose araC